Academic Journal
6‐Sulfatoxymelatonin as a predictor of clinical outcome in depressive patients
| العنوان: | 6‐Sulfatoxymelatonin as a predictor of clinical outcome in depressive patients |
|---|---|
| المؤلفون: | Hidalgo, Maria Paz Loayza, Caumo, Wolnei, Dantas, Giovana, Franco, Daiane Gil, da Silva Torres, Iraci Lucena, Pezzi, Julio, Elisabetsky, Elaine, Detanico, Bernardo Carraro, Piato, Ângelo, Markus, Regina P. |
| المصدر: | Human Psychopharmacology: Clinical and Experimental ; volume 26, issue 3, page 252-257 ; ISSN 0885-6222 1099-1077 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2011 |
| المجموعة: | Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: | Objectives This study established the value of the 6‐sulfatoxymelatonin (aMT6s) urine concentration as a predictor of the therapeutic response to noradrenaline reuptake inhibitors in depressive patients. Methods Twenty‐two women aged 18–60 years were selected. Depressive symptoms were assessed by using the Hamilton Depression Scale. Urine samples were collected at 0600–1200 h, 1200–1800 h, 1800–2400 h, and 2400–0600 h intervals, 1 day before and 1 day after starting on the nortriptyline treatment. Urine aMT6s concentration was analyzed by a one‐way analysis of variance/Bonferroni test. Spearman's rank correlation coefficient was used to analyze the correlation between depressive symptoms after 2 weeks of antidepressant treatment and the increase in aMT6s urine concentration. Results Higher and lower size effect groups were compared by independent Student's t ‐tests. At baseline, the 2400‐ to 0600‐h interval differed from all other intervals presenting a significantly higher aMT6s urine concentration. A significant difference in aMT6s urine concentrations was found 1 day after treatment in all four intervals. Higher size effect group had lower levels of depressive symptoms 2 weeks after the treatment. A positive correlation between depressive symptoms and the delta of aMT6s in the 2400–06 00h interval was observed. Conclusion Our results reinforce the hypothesis that aMT6s excretion is a predictor of clinical outcome in depression, especially in regard to noradrenaline reuptake inhibitors . Copyright © 2011 John Wiley & Sons, Ltd. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1002/hup.1204 |
| الاتاحة: | http://dx.doi.org/10.1002/hup.1204 https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhup.1204 https://onlinelibrary.wiley.com/doi/pdf/10.1002/hup.1204 |
| Rights: | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| رقم الانضمام: | edsbas.17AC9861 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/hup.1204 |
|---|